Literature DB >> 6998861

The immunoregulatory role of antigen-antibody complexes. I. Assessment of B and T-cell responses.

S Kaattari, R J Scibienski, E Benjamini.   

Abstract

The capacity of ovalbumin-anti-ovalbumin complexes to prime T cells preferentially without concomitant induction of antibody synthesis was investigated. Whereas free antigen injection into mice primed T and B lymphocytes and induced antibody production, injection of antigen-antibody complexes did not result in antibody production but did result in T-cell priming. However, the data suggest that, notwithstanding the lack of induction of antibody synthesis by immune complexes, a low degree of B-cell priming by the complex occurred; this priming was of IgM precursors only. The results indicate that the immunoglobulin isotype composition of the complex may be important to this preferential effect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6998861      PMCID: PMC1458492     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  The use of antigen-antibody specific precipitates in skin testing for delayed hypersensitivity.

Authors:  S LESKOWITZ
Journal:  J Immunol       Date:  1960-12       Impact factor: 5.422

2.  Regulation of the immune response. IV. Antibody-mediated suppression of the immune response to haptens and heterologous erythrocyte antigens in vitro.

Authors:  J W Kappler; A van der Hoven; U Dharmarajan; M Hoffmann
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

3.  Role of the Fc fragment in the regulation of the primary immune response.

Authors:  N R Sinclair; R K Lees; E V Elliott
Journal:  Nature       Date:  1968-12-07       Impact factor: 49.962

4.  Capacity of pepsin-digested antibody to inhibit antibody formation.

Authors:  T W Tao; J W Uhr
Journal:  Nature       Date:  1966-10-08       Impact factor: 49.962

5.  Recognition of lysozyme by lymphocyte subsets.

Authors:  R J Scibienski; V Klingmann; C Leung; K Thompson; E Benjamini
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

6.  Regulation of the immune response. I. Differential effect of passively administered antibody on the thymus-derived and bone marrow-derived lymphocytes.

Authors:  J W Kappler; M Hoffmann; R W Dutton
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

7.  Selective priming of T cells by chemically altered cell antigens.

Authors:  G Dennert; D F Tucker
Journal:  J Exp Med       Date:  1972-09-01       Impact factor: 14.307

8.  Delayed hypersensitivity. II. Induction of hypersensitivity in guinea pigs by means of antigen-antibody complexes.

Authors:  A M PAPPENHEIMER; S B SALVIN; J W UHR
Journal:  J Exp Med       Date:  1957-01-01       Impact factor: 14.307

9.  Immune responses against native and chemically modified albumins in mice. I. Analysis of non-thymus-processed (B) and thymus-processed (T) cell responses against methylated bovine serum albumin.

Authors:  V Schirrmacher; H Wigzell
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

10.  Occurrence of delayed hypersensitivity during the development of Arthus type hypersensitivity.

Authors:  S B SALVIN
Journal:  J Exp Med       Date:  1958-01-01       Impact factor: 14.307

View more
  3 in total

1.  IgG aggregates of different sizes stimulate or suppress Ig secretion by human lymphocytes in vitro.

Authors:  C Wiesenhutter; D W Knutson; D S Musgrave; R F Ashman
Journal:  J Clin Immunol       Date:  1984-03       Impact factor: 8.317

2.  Bovine milk IgG, but not serum IgG, inhibits pokeweed mitogen-induced antibody secretion by human peripheral blood mononuclear cells.

Authors:  A Kulczycki; G S Nash; M J Bertovich; H D Burack; R P MacDermott
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

Review 3.  Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.

Authors:  Xiao-Feng Sun; Hong Zhang
Journal:  Mol Cancer       Date:  2006-10-06       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.